I-REACH Scholar Program 2025 Open for Applications
Infrastructure for Research in Equity, Aging, Cancer and Health (I-REACH) has rolled out its Scholar Program call for applications for 2025.
The I-Reach Scholar Program goals are to:
- Expand the diversity of the scientific workforce at the intersection of aging, disparities and cancer.
- Create a multi-institutional, multi-disciplinary community devoted to accelerating discoveries and delivering interventions to reduce health disparities and increase health equity
Components of Scholar Program:
- Mentorship
- Specialized training
- Access to data and biospecimens
- Career skills and advancement
- Experience working with stakeholders
- Leadership opportunities (e.g., co-leading meetings, mentoring, leadership training)
- Impact future I-REACH
- Be matched with two I-REACH mentors who will advise them during the program
- Undergo CIMER training to maximize the impact of mentorship
- Complete I-REACH’s unique foundational curriculum on aging, disparities and cancer
- Have access to the Data and Stakeholder Cores to help design and refine research while using I-REACH’s multi-level framework
- Participate in Idea Labs, peer-to-peer writing groups, mock study sessions and will attend and co-lead monthly I-REACH meetings
- Design a research project and will be given preference when submitting their proposals for consideration in the Pilot Program, which will support and fund collaborative work
DETAILS:
Applications Due: Monday, February 3, 2025 at 11:59pm ET
Announcement of Awards: Tuesday, March 18, 2025
Start Date: July 2025
To apply and learn more on the I-Reach Scholar program visit the I-REACH website.
.
-
I-REACH Scholar Program 2025 Open for Applications
Apply to the 2025 Scholar Program by February 3, 2025.
Category: CRTEC Funding Opportunities
-
Black History Month Events at Georgetown
Explore the schedule of events in celebration of Black History Month.
Category: CRTEC News
-
Promising Phase III Melanoma Results Build on Research Conducted at Georgetown Lombardi
A promising new approach to preventing high-risk melanoma from recurring after surgery has yielded positive results in a large clinical trial, building on earlier research that included investigators and patients at Georgetown University’s Lombardi Comprehensive Cancer Center.
Category: Lombardi Stories
-
Preoperative Dual Immunotherapy Combination Shows Promising Activity in High-Risk Early-Stage HER2-Negative Breast Cancer
A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given prior to surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to phase 2 clinical trial results from the ongoing I-SPY2 clinical trial platform.
Category: News Release
-
Study Reveals Why Breast Cancer Becomes More Deadly with Age
Researchers at Georgetown’s Lombardi Comprehensive Cancer Center have identified a mechanism that may help explain a key reason why older people experience worse outcomes from breast cancer. The study implicates RAGE (Receptor for Advanced Glycation End-products), a cell surface receptor that amplifies inflammatory signaling, and which also becomes increasingly active with metastatic progression.
Category: News Release
-
Study Finds Teen Perceptions of Sun Protection and Tanning Shape Skin Cancer Risk Behaviors
A new study from Georgetown Lombardi researchers finds that how high school students perceive the costs of sun protection and the rewards of tanning play a significant role in whether they practice sun-safe behaviors.
Category: News Release
-
New Study Examines Stigma Toward Women Who Lose Weight Using GLP-1 Medications
In a new study exploring stigma associated with the use of GLP-1 drugs for weight loss, women who lost weight using GLP-1 medications were judged more harshly than those who lost weight through diet and exercise, with negative reactions driven largely by beliefs that medication-assisted weight loss is a “shortcut.” The study also found higher levels of stigma when the women in sample scenarios were portrayed as White rather than Black.
Category: News Release
-
Lombardi Gala Brings Together Friends, Supporters
A lineup of acclaimed performers took the stage at the 38th Annual Lombardi Gala for an evening of music, reflection and celebration in support of cancer research at Georgetown University’s Lombardi Comprehensive Cancer Center.
Category: Lombardi Stories
-
Dual Role of a Protein in Driving Bone Cancer in Children Discovered
Scientists at Georgetown University’s Lombardi Comprehensive Cancer Center have uncovered a new dual function for a well-known cancer-related protein called ezrin. This finding could potentially open the door to new treatments for osteosarcoma, the most common bone cancer in children and young adults, as well as other cancers that are ezrin-dependent.
Category: News Release
-
New Fund Honoring Dr. Louis Weiner Announced at Lombardi Gala
(March 15, 2026) — A surprise initiative to support future cancer researchers was unveiled at the annual Lombardi Gala on March 14, honoring Louis M. Weiner, MD, outgoing director of Georgetown’s Lom
Category: Special Stories
-
Louis M. Weiner, MD, to Step Down as Director of Georgetown’s Lombardi Comprehensive Cancer Center Following 18 Years of Leadership
After more than 18 years leading Georgetown University’s Lombardi Comprehensive Cancer Center, Louis M. Weiner, MD, has announced his decision to step down later this year.
Category: News Release
-
Reversing Immune Suppression in Pancreatic Cancer Could Lead to Novel Therapies
Georgetown Lombardi researchers discovered that when pancreatic cancer cells send out tiny particles that are packed with certain microRNA molecules, nearby immune cells called macrophages are reprogrammed to help the tumor grow instead of engaging in their regular role of fighting the tumor. This insight from cell and mouse experiments has helped the scientists outline a potential way to reverse the process and possibly improve outcomes in pancreatic cancer.
Category: News Release